<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171007036615N14</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-10-21</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Theory-Based Virtual Education on Health Literacy and Cervical Cancer Screening Behavior</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Virtual Education Based on the Fogg Model on Health Literacy and Stages of Behavior Change in Cervical Cancer Screening in Women: A Randomized Controlled Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/86293</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Screening, Randomization description: The study will include 80 participants, who will be allocated to either the intervention or control group by a person not involved in sampling, using random block allocation with the Random Allocation Software (RAS), employing blocks of 4 and 6 with a 1:1 ratio. The allocation will be written on paper and placed in sequentially numbered opaque envelopes (Allocation Concealment). The envelopes will be opened in the order of participants' entry into the study, Blinding description: The outcome assessor and data analyst in this study will be blinded to the allocation of participants to the groups. The initial outcome assessment before randomization will be conducted by the principal investigator (who administers the intervention). However, the outcome evaluation and data analysis will be performed by other individuals not involved in participant allocation, sampling, or intervention administration.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Cervical cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group: The intervention group will receive virtual education regarding cervical cancer and its screening. The content of the virtual intervention will be based on scientific evidence and aligned with the components of the Fogg Behavior Model, which includes videos (each video maximum two minutes), recorded audio (each recorded audio maximum two minutes), written messages, quizzes (simple written messages but in the form of questions and answers), and images containing educational messages (infographics). The main content titles are: the prevalence of cervical cancer in Iran and the world, the progression of the disease towards cancer, danger signs, ways to prevent cervical cancer and introduction of Pap smear, HPV test and available vaccines, guidelines of the Iranian Ministry of Health and the American College of Obstetricians and Gynecologists for screening. Following preparation, the content will be uploaded to a dedicated channel in the Eitaa messaging application. The intervention will be provided for 4 weeks; 2 times a week (every week on Mondays and Thursdays at 5 pm) along with reminders 2-3 times a week. In each content upload, a combination of the aforementioned formats will be used. Reminders will be delivered via SMS and phone calls. Immediately after uploading the materials, an initial SMS will be sent to participants, informing them of the upload and encouraging them to study the content. Participants will be requested to provide feedback by sending a private message with a 'like' symbol to the researcher once they have reviewed the materials. Additionally, if participants have any questions about the materials posted in the channel, they will receive the necessary guidance. In case of no feedback from the participant until 24 hours after uploading the materials, a second reminder SMS will be sent. In case of no feedback again until 48 hours, a phone call will be made to the participant. Intervention 2: Control group: The control group will not receive any intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data related to the study outcomes will be available for sharing.

When:
Access period starts 6 months after the results are published.

To whom:
The data will be available only to researchers working in academic and scientific institutions.

Conditions:
De-identified data available for meta-analysis or replication studies, with approval from the principal investigator.

Where to obtain:
By sending an email to the email address of Dr. Esmat Mehrabie: b.mehrabi62@gmail.com

How to obtain:
Emails sent by applicants to Dr. Esmat Mehrabi's email address (b.mehrabi62@gmail.com) will be responded to within one week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Saba Mousavi-Nejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing &amp; Midwifery, South Shariati St.,Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138947977</zip>
        <telephone>+98 41 3479 6770</telephone>
        <email>sabamnj@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Esmat Mehrabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery, South Shariati St., Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138947977</zip>
        <telephone>+98 41 3479 0364</telephone>
        <email>b.mehrabi62@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Married women aged 21 to 65 years
No history of Pap smear in the past three years or no intention to undergo it in the next six months
No personal history of cervical cancer or history of cervical cancer in first-degree relatives
Possession of a smartphone
Minimum education level of middle school
Verbal and auditory abilities, and the ability to use mobile applications
Scoring less than 99 on the Cervical Cancer Health Literacy Questionnaire</inclusion_criteria>
      <agemin>21 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Pregnant women
History of post-coital bleeding or irregular uterine bleeding
Self-reported history of genital warts
Current participation in related educational programs
History of atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, or high-grade squamous intraepithelial lesion
History of hysterectomy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C53</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of cervix uteri</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: The intervention group will receive virtual education regarding cervical cancer and its screening. The content of the virtual intervention will be based on scientific evidence and aligned with the components of the Fogg Behavior Model, which includes videos (each video maximum two minutes), recorded audio (each recorded audio maximum two minutes), written messages, quizzes (simple written messages but in the form of questions and answers), and images containing educational messages (infographics). The main content titles are: the prevalence of cervical cancer in Iran and the world, the progression of the disease towards cancer, danger signs, ways to prevent cervical cancer and introduction of Pap smear, HPV test and available vaccines, guidelines of the Iranian Ministry of Health and the American College of Obstetricians and Gynecologists for screening. Following preparation, the content will be uploaded to a dedicated channel in the Eitaa messaging application. The intervention will be provided for 4 weeks; 2 times a week (every week on Mondays and Thursdays at 5 pm) along with reminders 2-3 times a week. In each content upload, a combination of the aforementioned formats will be used. Reminders will be delivered via SMS and phone calls. Immediately after uploading the materials, an initial SMS will be sent to participants, informing them of the upload and encouraging them to study the content. Participants will be requested to provide feedback by sending a private message with a 'like' symbol to the researcher once they have reviewed the materials. Additionally, if participants have any questions about the materials posted in the channel, they will receive the necessary guidance. In case of no feedback from the participant until 24 hours after uploading the materials, a second reminder SMS will be sent. In case of no feedback again until 48 hours, a phone call will be made to the participant.</i_keyword>
      <i_keyword>Control group: The control group will not receive any intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cervical cancer health literacy score. Timepoint: before the intervention and 4 weeks after the completion of the intervention. Method of measurement: Cervical Cancer Health Literacy Questionnaire by Bazaz et al. (2019).</prim_outcome>
      <prim_outcome>Frequency of stages of behavioral change for cervical cancer screening. Timepoint: before the intervention and 8 weeks after the completion of the intervention. Method of measurement: Behavioral Change Stages Checklist (Prochaska).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Decision-making self-efficacy score. Timepoint: before the intervention and 4 weeks after the completion of the intervention. Method of measurement: Decision Self-Efficacy scale.</sec_outcome>
      <sec_outcome>Anxiety score. Timepoint: before the intervention and 4 weeks after the completion of the intervention. Method of measurement: Spielberger State Anxiety Inventory (Form 1).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-09-08</approval_date>
        <contact_name>Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Central Building, Tabriz University of Medical Sciences, Golgasht St., Tabriz Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
